Suppr超能文献

COVID-19 患者伴意义未明的单克隆免疫球蛋白血症 IgM 型冷自身免疫性溶血性贫血,经皮质类固醇治疗后成功缓解。

Severe Anemia Due to Cold Agglutinin Syndrome in a COVID-19 Patient with IgM Monoclonal Gammopathy of Undetermined Significance Successfully Treated with Corticosteroids.

机构信息

Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Japan.

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.

出版信息

Intern Med. 2022 Jun 1;61(11):1789-1793. doi: 10.2169/internalmedicine.8647-21. Epub 2022 Mar 26.

Abstract

Secondary cold agglutinin syndrome (CAS) is autoimmune hemolytic anemia secondary to infections and lymphoid disorder. We here report the first Asian case of CAS secondary to novel coronavirus disease 2019 (COVID-19). A 72-year-old Japanese woman presented with a 2-week history of dyspnea and cough, and laboratory data revealed severe hemolytic anemia with a hemoglobin level of 4.7 g/dL. She was diagnosed with COVID-19, CAS, and monoclonal gammopathy of undetermined significance (MGUS). The anemia responded to corticosteroids administered for COVID-19 and required maintenance therapy. Although corticosteroids are not a standard therapy for CAS, they might be effective for CAS secondary to COVID-19 complicated with MGUS.

摘要

继发冷自身免疫性溶血性贫血(secondary cold agglutinin syndrome,CAS)是继发于感染和淋巴系统紊乱的自身免疫性溶血性贫血。我们在此报告首例新型冠状病毒病(COVID-19)继发 CAS 的亚洲病例。一名 72 岁日本女性因呼吸困难和咳嗽 2 周就诊,实验室数据显示严重溶血性贫血,血红蛋白水平为 4.7g/dL。她被诊断为 COVID-19、CAS 和意义未明的单克隆丙种球蛋白病(monoclonal gammopathy of undetermined significance,MGUS)。贫血对 COVID-19 给予的皮质类固醇治疗有反应,需要维持治疗。虽然皮质类固醇不是 CAS 的标准治疗方法,但对于 COVID-19 合并 MGUS 继发的 CAS 可能有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f136/9259319/e69d553031c8/1349-7235-61-1789-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验